Company Overview and News

5
E-L Financial - 38% Discount To A Growing Book Value With A Potential Catalyst

2018-06-25 seekingalpha
E-L Financial (OTCPK:ELFIF) is a holding company. It's a quiet, Canadian-style holding company, long owned by the Jackman family, who founded it. The management team is one of the least promotional I've ever seen; the company doesn't even have a website. Of course, it does file its financials with the Canadian equivalent of the SEC. Given those financials are in Canadian dollars and the company trades more volume in Canada under the symbol ELF, all figures in this report are in that currency unless otherwise noted.
UNC AGMJF EVT ECVTF GWLOF GWO ELF MFC GWLIF UCPLF ALC SLF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:UNC / United Corp Ltd on message board site Silicon Investor.

Dutch Central Bank Sale Announcement Imminent? Dutch Central Bank Sale Announcement Imminent? Dutch Central Bank Sale Announcement Imminent? IRID - Iridium World Communications IPO Announced! IRID - Iridium World Communications IPO Announced! IRID - Iridium World Communications IPO Announced!
Indications -- obesity/erectile dysfunction Indications -- obesity/erectile dysfunction Indications -- obesity/erectile dysfunction AgJunction Inc. - HW/SW for Precision Agriculture AgJunction Inc. - HW/SW for Precision Agriculture AgJunction Inc. - HW/SW for Precision Agriculture
Munch-a-Biotech Today Munch-a-Biotech Today Munch-a-Biotech Today Attractive opportunities in already announced mergers Attractive opportunities in already announced mergers Attractive opportunities in already announced mergers
MBRX under $3 announced big break through for Leukemia MBRX under $3 announced big break through for Leukemia MBRX under $3 announced big break through for Leukemia Rite Aid and Walgreens announcing merger tomorrow Rite Aid and Walgreens announcing merger tomorrow Rite Aid and Walgreens announcing merger tomorrow
Buckeyu0027s Bottom Bounce Short Term Picks (CDN ONLY) Buckeyu0027s Bottom Bounce Short Term Picks (CDN ONLY) Buckeyu0027s Bottom Bounce Short Term Picks (CDN ONLY) Cyan Inc., Software Defined Networking and Network Function Cyan Inc., Software Defined Networking and Network Function Cyan Inc., Software Defined Networking and Network Function